Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fidaxomicin vs. Vancomycin for Clostridium difficile in Spinal Cord Injury
NCT02355938Phase 4Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fidaxomicin in Clostridium difficile infection (CDI), sponsored by Baylor College of Medicine. Primary endpoint: Cure of Clostridium Difficile at 10 days. Started Feb 2014; status: terminated.
02
Drugs
fidaxomicin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT02355938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02355938.